Wall Street's Insights Into Key Metrics Ahead of Globus Medical (GMED) Q4 Earnings

Core Insights - Wall Street analysts forecast that Globus Medical (GMED) will report quarterly earnings of $1.06 per share, reflecting a year-over-year increase of 26.2% [1] - Anticipated revenues for the quarter are projected to be $787.85 million, indicating a 19.9% increase compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term price performance [3] Key Metrics Projections - Analysts project 'Net Sales by Product Category- Enabling Technologies' to reach $33.70 million, a decrease of 28.2% from the prior-year quarter [5] - The average estimate for 'Net Sales by Product Category- Musculoskeletal Solutions' is $735.95 million, suggesting a year-over-year increase of 20.6% [5] - Estimated 'Geographic Revenues- International' are projected at $147.72 million, reflecting a 9.1% increase year over year [6] - 'Geographic Revenues- United States' are expected to reach $621.92 million, indicating a 19.2% increase from the year-ago quarter [6] Stock Performance - Globus Medical shares have experienced a decline of 4.3% in the past month, compared to a 0.8% decline in the Zacks S&P 500 composite [6] - With a Zacks Rank 2 (Buy), GMED is expected to outperform the overall market performance in the near term [6]